Testing the impact of a innovative digital resource, ActionPlan, on familial cancer patient empowerment.

Who is it for? You may be eligible for this study if you are a male or female over the age of 18, and test positive in a NATA-accredited molecular laboratory for a germline likely pathogenic (Class 4) or pathogenic (class 5) variant in either BRCA1, BRCA2 or PALB2 genes during the period of the trial, and have no current cancer diagnosis of any type, or previous diagnosis of breast, ovary or prostate cancer. Study details In this Hybrid two effectiveness and Implementation trial, participants will be randomly allocated to 1) access to the Website - ActionPlan, 2) access to ActionPlan with telephone conversation one month after access to improve uptake of the website or 3) standard care. In the Website ActionPlan arm, participants will receive personalised interactive risk graphics, and information modules -breast cancer risk reduction /screening, ovarian cancer risk reduction, lifestyle factors, psychological support, grief support, reproductive options, family communication and cascade tool, rarer cancers and research opportunities. The website can be accessed at the participant discretion. In the ActionPlan and telephone conversation arm, participants will receive access to the website ActionPlan and a follow up telephone call one month after access to ActionPlan using behaviour change theory aimed at addressing any digital or health literacy issues. Participants will be followed up at baseline, 2 , 5 and 8 months post intervention commencement to assess for patient empowerment, coping with a genetic diagnosis, and decisional conflict. It is hoped that this study will contribute to our understanding of digital interventions in healthcare, and improve person-centred care by empowering participants to be more actively engaged in in their health and values- based decision making.